Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0034186 (
pyelonephritis
)
6,144
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Pefloxacin (Abaktal) was used in treatment of 83 patients: 14 patients with acute
pyelonephritis
, 5 patients with carbuncle of the kidney, 17 patients with postoperative acute
pyelonephritis
, 3 patients with urosepsis, 7 patients with acute prostatitis, 18 patients with chronic
pyelonephritis
in the phase of active inflammation, 9 patients with exacerbation of chronic prostatitis, 3 patients with acute cystitis, 2 patients with acute urethritis and 5 patients with epididymo-orchitis. Two dosage forms of pefloxacin were used i.e. tablets of 400 mg and ampoules of 5 ml containing 400 mg of the active substance. The treatment course amounted to 7-14 days. In the patients with inflammatory infectious diseases of the lower urinary tracts (cystitis and urethritis) the treatment course amounted up to 5 days. The results of the treatment with the ampoule solutions were good and satisfactory. With the use of the tablets the results were unsatisfactory in 3 patients (8.1 per cent). Satisfactory bacteriological efficacy of the treatment was stated in 89.5 per cent of the cases. The adverse reactions such as nausea,
vomiting
, diarrhea and skin eruption were recorded in 5 patients (6 per cent).
...
PMID:[Clinical effectiveness of pefloxacin (abaktal)in the treatment of inflammatory diseases of the kidneys, urinary tracts and genital organs]. 807 66
Various treatment strategies are currently used in the management of acute
pyelonephritis
, with some patients being treated as inpatients and others as outpatients. To better describe the clinical course of patients with this condition and the management strategies of physicians treating these patients, a retrospective cohort study of febrile nonpregnant women presenting to the emergency department with clinical evidence of acute
pyelonephritis
was conducted. Acute pyelonephritis was defined as infected urine (> or = 7 white blood cells/high-power field and/or urine culture with > or = 10(4) colony-forming units [CFU]/mL) and fewer (> or = 37.8 degrees C) without other source. Between October 1990 and September 1991, 28 hospitalized and 83 nonhospitalized patients satisfied these criteria. Data were abstracted from hospital charts, and clinical outcomes were determined from chart reviews and telephone or mailed questionnaires. The hospitalized patients were significantly older (odds ratio [OR] = 1.07), had higher temperatures (OR = 6.12), and were more likely to have diabetes (OR = 10.57), genitourinary tract abnormalities (OR = 10.53), and
vomiting
(OR = 12.17) than the nonhospitalized patients. Sixty-six (80%) of the nonhospitalized patients were treated with a single dose of parenteral antibiotic (usually gentamicin or ceftriaxone) before discharge on oral antibiotics. Seventy-one (86%) were treated with oral trimethoprim-sulfamethoxazole. Follow-up was obtained for 75 (90%) of the nonhospitalized patients. Nine (12%) of the 75 returned because of symptoms of acute
pyelonephritis
, with 8 returning within 1 day of the initial visit. Seven of those returning were admitted. All responded to additional antibiotic therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:ED management of acute pyelonephritis in women: a cohort study. 817 29
We report the case of a 61-year-old woman, who suffered from abdominal pain, nausea,
vomiting
and fever. She had a past medical history of acute rheumatism,
pyelonephritis
and systemic scleroderma. Since 1971 she was hospitalized many times because of recurrent abdominal pain with increased serum amylase and lipase values. On admission, she was in distress and demonstrated clinical signs of acute pancreatitis. The link between systemic lupus erythematosus and acute pancreatitis is discussed in view of the reported cases of the world literature.
...
PMID:Pancreatitis in systemic scleroderma. 936 Feb 94
Nausea and vomiting are common problems of pregnancy. Three pregnant women, 27, 25 and 28 years of age, presented with
vomiting
in the third trimester. The causes appeared to be maternal small bowel volvulus, which was derotated after primary caesarean section, an ileocecal abscess, which was the first manifestation of Crohn's disease, and acute
pyelonephritis
, treated with cefuroxim. The second and third babies were born spontaneously; no maternal or foetal mortality occurred. Persistent vomiting after the first trimester of pregnancy should be considered an alarm symptom which always requires further investigation.
...
PMID:[Vomiting after the first trimester of pregnancy: an alarming symptom]. 964 5
Antimicrobial therapy for
pyelonephritis
in children must quickly eradicate the bacterial infection and prevent scars in renal parenchyma. Escherichia coli (E Coli) is found in about 90% of cases of acute
pyelonephritis
in outpatients, 40% of E coli being ampicillin-resistant. The present effective antibiotics are: 3rd-generation cephalosporines, amoxicillin-clavulanic acid association, and aminoglycosides. In the literature therapeutical guides are divergent concerning the route of administration (oral or i.v.), mono or bitherapy, the duration of the treatment (usually for 10 days), and the need for hospitalisation. The criteria for choice are risk factors such as: very young age (< 6 months), fever with toxic symptoms,
vomiting
, dehydration, uropathy, and poor compliance. There are few long term studies which compare two, therapeutic regimens and no evaluation of the frequency of consequent chronic
pyelonephritis
in adult age has taken place. Recent data suggest that an oral sequential treatment may permit a shorter hospital stage. The trend is chiefly to do bona fide recommendations more than elaboration of a true consensus.
...
PMID:[Antibiotic treatment of acute pyelonephritis in the child]. 975 22
Ciprofloxacin, a recently released oral fluorinated quinolone structurally related to nalidixic acid, joins norfloxacin as the second drug of this class to be released. Ciprofloxacin has a wide spectrum of antimicrobial activity and importantly demonstrates little cross resistance to non-quinolone drug classes (e.g. ureidopenicillins, cephalosporins, monobactams, carbapenems, aminoglycosides). Unlike other antibacterial classes such as the beta-lactams or aminoglycosides, ciprofloxacin does not suffer from transferable plasmid-mediated (i.e. R-factor) antibiotic resistance. Against gram-positive (including penicillin-resistant and methicillin-resistant staphylococci aureus) and gram-negative aerobic bacteria including Pseudomonas aeruginosa, ciprofloxacin demonstrates excellent activity. Ciprofloxacin is inactive against Trichomonas sp., treponemes, and fungi and anaerobes are considered resistant. Ciprofloxacin is rapidly absorbed from the gastrointestinal tract (i.e. 70-80% bioavailable), demonstrates extensive extravascular distribution, and its 3.5-5 hour half-life allows twice daily dosing. The bacteriologic and clinical efficacy of oral ciprofloxacin was shown to be comparable to third generation cephalosporins or aminoglycosides for osteomyelitis, cefotaxime for skin structure infections, and to a combination of tobramycin with azlocillin for pulmonary exacerbation of cystic fibrosis. Adverse events associated with ciprofloxacin are related mostly to gastrointestinal disturbance and consist of nausea/
vomiting
or diarrhea. Concomitant administration of ciprofloxacin and theophylline may lead to decreased theophylline clearance and necessitates periodic measurements of theophylline levels to avoid toxic levels. Treatment with oral ciprofloxacin should offer substantial cost savings over a variety of parenteral antimicrobial regimens (e.g. aminoglycoside + beta-lactams) for difficult to treat infections such as chronic
pyelonephritis
, osteomyelitis, and skin structure infections. Consideration of important precautions (e.g. contraindications, drug interactions) and potential disadvantages (e.g. emergence of resistance) must also guide the rational use of oral ciprofloxacin.
...
PMID:Focus on oral ciprofloxacin; clinical and economic considerations. 1029 99
Treatment of UTI with oral antibiotics alone is generally effective, even in young children with
pyelonephritis
. Cefixime has a broad spectrum of activity and is suitable as an empiric agent in most cases. In patients who are unlikely to tolerate oral medications because of
vomiting
or who appear toxic on examination, hospitalization and initial treatment with i.v. therapy is indicated. In general, radiographic studies can be performed prior to completion of the primary course of antibiotics, and prophylactic treatment is unnecessary. Patients should receive instruction about the risk of recurrent infection and should be advised to seek medical attention when symptoms of UTI develop.
...
PMID:Treatment of urinary tract infections. 1057 43
Emphysematous pyelonephritis is a rare life threatening infection in diabetes characterised by suppurative infection of renal parenchyma and perirenal tissues. It usually presents with fever, nausea,
vomiting
, abdominal pain, shock, lethargy, and confusion. Diabetic ketoacidosis is an uncommon presentation. In the present case, an elderly female presented with abdominal pain, fever,
vomiting
, and altered sensorium. She was diagnosed to have diabetic ketoacidosis with metabolic encephalopathy with right emphysematous
pyelonephritis
. She had an excellent response to medical treatment alone and was later discharged on oral hypoglycaemic agents.
...
PMID:Emphysematous pyelonephritis: a rare presentation. 1085 76
In this work the authors reported the case of a 29-year-old woman, who had been dialysed since 1997 in the course of chronic
pyelonephritis
caused by vesicoureteral reflux. Due to the detrusor vesica urinariay's hypofunction (confirmed by repeated urodynamic studies) the patient was prescribed Baclofen with a dosage of 2 x 10 mg per 24 hours. In the course of Baclofen's therapy, toxic effects of the drug like weakness, nausea,
vomiting
and fears appeared during the second day of treatment. They had been increasing since the patient's admission to the Dialysis Centre where she had immediately undergone the planned haemodialysis. After the initial increase of the poisoning symptoms including the loss of consciousness, patient's state of health improved after approximately two hours since the haemodialysis had been performed. After five more days in hospital, the patient was discharged in general good condition (two more planned haemodialyses were performed at the time of treatment).
...
PMID:[Toxic effects of baclofen in a patient with chronic renal insufficiency]. 1145 Mar 71
Quinupristin/Dalfopristin is a new combination of streptogramin antibiotics designed specifically to treat clinically significant infections due to Vancomycin-resistant Enterococcus Faecium. Sweet's syndrome is characterized by painful skin plaques, which is associated with dermal neutrophilic infiltration, fever and peripheral blood leukocytosis. Drug-induced Sweet's syndrome has a temporal relationship between drug ingestion, clinical presentation and the temporally-related resolution of lesions following drug withdrawal or on treatment with systemic corticosteroids. A 63-year-old woman received Quinupristin/Dalfopristin for acute
pyelonephritis
developed fever, arthralgia,
vomiting
, and painful erythematous skin plaques. A skin biopsy showed neutrophilic dermatosis, and there was rapid resolution of the symptoms and cutaneous lesions after discontinuation of Quinupristin/Dalfopristin, consistent with drug-induced Sweet's syndrome. To date, there has been no reported case of Sweet's syndrome associated with the use of Quinupristin/Dalfopristin.
...
PMID:Quinupristin/dalfopristin-induced Sweet's syndrome. 1461 89
<< Previous
1
2
3
4
5
Next >>